Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Abbott discloses nicotinic cholinergic channel modulators

Feb. 18, 1997

Adenosine kinase inhibitors prepared by Gensia

Feb. 18, 1997

Ampalex trial in AD begins

Feb. 17, 1997

GDNF gene therapy for Parkinson's disease

Feb. 17, 1997

Third launch for Zyprexa

Feb. 17, 1997

Nymox drug candidate for AD to enter phase I

Feb. 14, 1997

HMR synthesizes potent AChE inhibitor

Feb. 14, 1997

Paroxetine inhibits NOS

Feb. 13, 1997

Valproate efficacy in major depressive disorder

Feb. 13, 1997

Encouraging phase IIb results for antiparkinsonian patch

Feb. 13, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...